Status: Not yet recruiting
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period. The present study is being undertaken to fulfill the Post Marketing Surveillance (PMS) mandate by the Health Authority (HA) to evaluate the safety of secukinumab solution for injection administered subcutaneously in a pre-filled pen in the indicated population under real-world clinical practice conditions.
Participants needed: 60
Trial details
Age: 18-100Biological sex: AllType: ObservationalSponsor: Novartis PharmaceuticalsUpdated: Jul 30, 2026
Eligibility criteria
Participant or his/her legally acceptable representative (LAR) who are willing t... [+1]
Participants who meet any contraindication outlined in the current Prescribing I... [+2]